INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018 - 13-15 SEPTEMBER MADRID, SPAIN
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
ADVANCING IMMUNO-GENE THERAPY
ACROSS DISEASES
INTERNATIONAL
CONFERENCE ON
LYMPHOCYTE
ENGINEERING
2018
13-15 SEPTEMBER
MADRID, SPAIN
PROGRAMME
LYMPHOCYTE.KENES.COM
#ICLE2018 #ICLE2018 1
Kenes
Original events
What hOW turning iDeas
intO
reality!
is a Kenes DOes it
Original event?
WOrK?
We invest in emerging We support individuals We combine the right
topics to create new and institutions with resources and deliver a
platforms for knowledge unique ideas to create high quality, memorable
exchange in the form leading conferences in participant experience.
of independent event the field. Let’s turn your ideas into
brands. real prosperous events!
Kenes Original events POrtfOliO
2 WWW.Kenes.cOm
INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018 TABLE OF CONTENTS CONFERENCE INFORMATION Welcome 4 Venue Map 5 General Information 6 Information for Oral Presenters and Chairpersons 8 Information for E-Poster Presenters and Chairpersons 9 Poster Presentations 10 SCIENTIFIC PROGRAMME Thursday, 13th September 12 Friday, 14th September 14 Saturday, 15th September 18 RECOGNITION, ACKNOWLEDGEMENTS & INDUSTRY SUPPORT Acknowledgements 21 Company Profiles 22 ICLE WELCOME RECEPTION 24 GETTING AROUND IN MADRID 25 #ICLE2018 3
WELCOME
Dear Colleagues,
It is our great pleasure to welcome you to the first International Conference on Lymphocyte
Engineering (ICLE) 2018!
Great strides have been made in recent years in the engineering of lymphocytes for the
treatment of cancer, autoimmune diseases, pathogenic diseases and primary immune
deficiencies. Combining gene therapy, cell therapy and immune therapy, the emerging
field of lymphocyte engineering employs cutting edge technologies of viral and non-viral
vectorology, genome editing and protein design as well as advanced clinical protocols for
cell harvest, expansion and re-infusion. With groundbreaking clinical success leading
to FDA approved products and with vibrant, exponentially growing research, lymphocyte
engineering is the wave of the future.
Still, the challenges are formidable and the stakes are high. Realizing the full promise of
lymphocyte engineering will require the combined efforts of a dedicated community. ICLE
2018 is our way to facilitate the sharing of data and ideas, promote collaborations, and
address common challenges to advance clinical translation. We set the aim to provide an
effective environment for active learning, discussions of real-world case studies and for
networking between like-minded peers.
It is time to catch the wave of what is most pioneering and innovative in lymphocyte
engineering!
On behalf of the Advisory Board,
Adi Barzel
President of the Israeli Society for Gene and Cell Therapy (ISGCT),
ICLE conference chair,
Senior lecturer at Tel-Aviv University
4
INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
VENUE MAP
LEVEL 4
ZARAGOZA II ZARAGOZA I
PLENARY HALL
ENTRANCE
REGISTRATION AREA
Res
ear
ZARAGOZA III & IV 02 06 TT5
ch T
hea
ter
e-Poster
Exhibitor Booth No Logo
CellGenix 2
GeneWerk TT5
VIVEbiotech 6
#ICLE2018 5GENERAL INFORMATION
HOTEL VENUE
Meliá Avenida America, Calle de Juan Ignacio Luca de Tena, 36, 28027 Madrid, Spain
Tel: + (34) 914232400
REGISTRATION DESK HOURS
Thursday, 13 September 08:00 – 18:00
Friday, 14 September 07:30 – 18:00
Saturday, 15 September 07:30 – 16:00
EXHIBITION OPENING TIMES
Thursday, 13 September 10:00 – 18:00
Friday, 14 September 10:00 – 18:00
Saturday, 15 September 09:30 – 14:00
PARTICIPANTS BADGE
Upon registration, you will receive your name badge. You are kindly requested to wear your
badge during all sessions and events.
WI FI
Free WIFI will be available at the Conference. Please be aware that public WIFI capacity is
always limited and therefore limited to email and web browsing activity.
Network: icle18
Password: icle18madrid
1:1 MEETINGS
During the conference days you will have an opportunity to arrange 1:1 meetings with
Faculty members, Exhibitors and other Attendees you want to meet in person and share
your experience and ideas in the field of lymphocyte engineering. Just install the ICLE
Meeting Diary interactive mobile app to your smartphone or portable devices and:
• Access your Personal Meeting Agenda;
• Request/ Accept or Decline meeting invitations with the people you want
at the designated meeting time slots available during the coffee and lunch
breaks in the Exhibition & Networking area.
• Check the Full Conference Agenda;
• Keep the Conversation Going in Social Media
To run the application you may choose one of the options below:
1 Scan the QR code. Your ID is the email you used to register for the conference; The default
password is ICLE2018. To change the default pass and set your personal one you may
click on the forgotten password link and follow the steps;
2 Click on the link that will be sent to your personal email. You will be automatically logged
into the app.
6INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
REFRESHMENTS AND LUNCH
Refreshments and lunch will be served in the Exhibition & Catering Hall (Zaragoza Hall 3&4,
Level 4) at the times indicated on the timetable.
ABSTRACTS
All accepted abstracts are published in the November issue of Human Gene Therapy online
journal. A link to the journal is also published on the conference website.
PHOTOGRAPHY AND RECORDING PRIVILEGES
No photographs, video recording or audio recording is permitted in the scientific sessions
unless otherwise authorized by the Advisory Board.
MOBILE PHONES
Mobile phones must be muted during all sessions.
GUEST ATTENDANCE POLICY
All event activities (including meal functions, exhibition, etc.) are exclusively reserved for
registered attendees. Non-registered guests (including children, family members, col-
leagues, etc.) are not allowed in any of the event areas. Badges provided at registration are
required for entrance into all functions and will be strictly enforced.
LIABILITY AND INSURANCE
The Conference Secretariat and Organizers cannot accept liability for personal accidents or
loss of or damage to private property of participants. Participants are advised not to leave
their personal belongings unattended in session halls and throughout the Venue hotel.
SMOKING POLICY
Smoking is prohibited throughout the Venue hotel. Please be considerate of the rules of the
venue and your fellow-participants.
SOCIAL MEDIA
Join us on Facebook, Twitter and LinkedIn to start advancing research, clinical translation
and treatment in immuno-gene therapy across related disease specialties and keep the
conversation going after the event.
Use the conference hashtag #ICLE2018 to let people know what is going on during the event!
LOCAL INFORMATION
Please visit the hotel concierge for local information.
CONFERENCE SECRETARIAT
www.lymphocyte.kenes.com
Rue François- Versonnex 7, 1207 Geneva, Switzerland.
www.kenes.com
#ICLE2018 7INFORMATION FOR ORAL PRESENTERS
AND CHAIRPERSONS
Please check the PROGRAMME in case of last minute scheduling changes.
PRESENTATION FORMAT
Invited Speakers will have 20 minutes for presentation which include 15 minutes for their
talk + 5 minutes for questions and discussion.
Oral Abstract Presenters will have 15 minutes for presentation which include 10 minutes
for their talk + 5 minutes for questions and discussion.
ORAL COMMUNICATIONS
As Oral Communication speakers you are requested to arrive at least 1 hour before your
session in order to provide the Speaker Ready Desk with your slides. If using a Power Point
(or any other computer) presentation, please note you need to bring it on a memory stick
(using the USB port in the computer).
We strongly recommend not using own computers for presentation – please note that the
time used for connecting own computer will be deducted from the total presentation time.
However, if you choose to use your own computer please note it has to have HDMI socket
for external signal. In such a case please come to update the AV support about it and come
to test in the session hall during a coffee or lunch break prior to your session, at least 30
minutes before the start of the session.
VIDEO FILMS IN YOUR PRESENTATION
If combining video films with PowerPoint, please make sure to check it in the session hall
during a coffee or lunch break prior to your session, at least 30 minutes before the start of
the session.
8INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
INFORMATION FOR E-POSTER
PRESENTERS AND CHAIRPERSONS
There will be E-Poster Presentation Sessions in the coffee breaks during all conference
days as well as in the lunch break on 15th September. All participants are invited to
the E-Poster Presentation Station to hear the selected short presentations and to ask
questions.
All E-Posters can also be viewed during the conference days on a separate E-Poster Station,
located in the E-Poster Viewing Area in the same hall.
Location: Zaragoza Hall 3&4, Level 4
ePoster Session Date & Time Chairman
Session 1 13th September
Sonia Guedan (Spain)
Hematological Malignancies 16:00 – 16:40
Session 2
14th September
Safety switches & controlled expression/ Tal Akriv (Israel)
10:20 – 11:00
Hematological Malignancies
Session 3
14th September
Target & Receptor discovery/Non-viral Natalia Gritsenko (Israel)
15:30 – 16:10
vectors
Session 4 15th September
Yuval Raviv (Israel)
Safety switches and controlled expression 10:00 – 10:30
Session 5 15th September
Daniel Nataf (Israel)
Solid Tumors/Other 12:00 – 13:30
#ICLE2018 9POSTER PRESENTATIONS
The main opportunity for standard poster viewing and discussion is during the lunch and
coffee breaks each day and authors are requested to stand by their poster to answer
questions.
Location: Zaragoza Hall 3&4, Level 4
POSTERS
Topic /Abstract Title Board
GENOME EDITING AND ALLOGENEIC ACT
TIM-3 TARGETING CAR-T CELLS, AS A POTENTIAL IMMUNOTHERAPY FOR AML. 1
S. Lee, Z.Y. Ye, H. Huang, M.K. Soh, Cheng-I WANG (Singapore)
HEMATOLOGICAL MALIGNANCIES
KINETICS OF EXPANSION AND PHENOTYPE OF UCART19 CELLS IN THE FIRST CLINICAL 2
TRIAL OF A UNIVERSAL ALLOGENEIC CAR-T CELL PRODUCT
A. Jozwik, C. Graham, A. Dunlop, K. Sanchez, D. Yallop, P. Patten, A. Pagliuca, G. Mufti, L.
Gauthier, A. Zinai, S. Dupouy, S. Balandraud, C. Poirot, A. Philippe, F. Simon, C. Konto, B.
Ganguly, T. Pertel, B. Sasu, R. Benjamin (UK)
CLINICAL MANUFACTURING OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR 3
ADOPTIVE IMMUNOTHERAPY
K. Mølgaard, Ö. Met, I.M. Svane (Denmark)
DETECTION NPM1 MUTATION AND CLINICAL CHARACTERS IN ADULT PATIENTS WITH 4
ACUTE MYELOID LEUKEMIA IN THE MONGOLIA
S. Oyunbileg, B. Davaabayar, N. Oyunderlger, B. Sevjidma (Mongolia)
DETECTION FLT3/ITD MUTATION AND CLINICAL CHARACTERS IN ADULT PATIENTS WITH 5
ACUTE MYELOID LEUKEMIA IN THE MONGOLIA
S. Oyunbileg, B. Davaabayar, B. Khishigjargal, N. Oyundelger, B. Sevjidmaa (Mongolia)
OTHER
CUMULATIVE CHEMOTHERAPY DEPLETES NAÏVE T CELLS : IMPLICATIONS FOR 6
CELLULAR THERAPY
D. Barrett, R. Das, J. Storm (USA)
EXPRESSION AND FUNCTIONAL DYNAMICS OF TRPV1 ION CHANNEL IN THE CANINE PBMC 7
J. Bujak, P. Bednarczyk, D. Kosmala, I. Szopa, K. Majchrzak (Poland)
10INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018 CLINICAL-GRADE ASPERGILLUS-SPECIFIC T CELLS: SWITCH FROM MAGNETIC SELECTION 8 WITH LYSATE TO SHORT TERM EXPANSION PROCEDURE WITH PEPTIDE POOLS C. Hoffmann-Freimüller, R. Geyeregger, S. Tischer, N. Frank, J. Stemberger, B. Maecker- Kolhoff, R. Blasczyk, G. Fritsch, B. Eiz-Vesper (Austria) COMPREHENSIVE ANALYSIS OF STARTING MATERIALS FOR GENE-MODIFIED CELL- 9 BASED IMMUNOTHERAPIES A. Luostarinen, S. Ylä-Herttuala, J. Nystedt, T. Kaartinen (Finland) OPTIMISATION OF CYTOKINE-DEPENDENT EXPANSION FOR TCR-TRANSDUCED 10 AUTOLOGOUS T-CELLS R. Petrovic, D. Biziato, A. Toufexi, J. Kerby (UK) CTSTM DYNABEADSTM CD3/CD28 ENABLES SIMULTANEOUS ONE-STEP NAÏVE AND 11 EARLY MEMORY T ISOLATION AND ACTIVATION T.E. Stav-Noraas, R. Hartberg, T. Looney, L. Miller, G. Lowman, H. Almåsbak (Norway) IMPACT OF THE SIGNAL STRENGTH AND TEMPERATURE DURING T LYMPHOCYTES 12 ACTIVATION AND PROLIFERATION - STUDY ON COMPANION DOG MODEL I. Szopa, J. Bujak, A. Łabedz, K. Majchrzak (Poland) SAFETY SWITCHES AND CONTROLLED EXPRESSION PRECLINICAL OPTIMIZATION OF CHIMERIC ANTIGEN RECEPTOR CD123-EXPESSING 13 T-CELLS FOR ACUTE MYELOID LEUKEMIA AND INCLUSION OF AN INDUCIBLE CASPASE 9 SUICIDE GENE TO INCREASE SAFETY M.L. Baroni (Spain) SOLID TUMORS GENETIC ENGINEERING OF TUMOUR INFILTRATING LYMPHOCYTES (TIL) WITH A NOVEL 14 GROWTH FACTOR RECEPTOR FOR TREATMENT OF SOLID TUMOURS M. Le Brocq, G. Owens, J. McCaffrey, A. Patel, R.D. Guest, R.E. Hawkins, J.S. Bridgeman (UK) A CAR-T CELL THERAPY TARGETING GLYPICAN-3 POSITIVE HEPATOCELLULAR 15 CARCINOMA B. Wang, E. Ngoh, M.K. Soh, Y. Yeap, H. Huang, H.C. Tan, Y. Hu, C.I. Wang (Singapore) TARGET AND RECEPTOR DISCOVERY OPTIMISING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR HAEMATOLOGICAL 16 MALIGNANCIES A. Bahashwan, M. Kalaitsidou, A. Schutt, D. Gilham, R. Hawkins (UK) #ICLE2018 11
SCIENTIFIC PROGRAMME
THURSDAY, 13 SEPTEMBER 2018
11:00 – 11:15 Zaragoza I & II
WELCOME ADDRESS
Adi Barzel (Israel)
11:15 – 13:00 SESSION 1
CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES
Chair: Michal Besser (Israel)
11:15 KEYNOTE LECTURE
ACCELERATING THE EVOLUTION OF CELL THERAPY
Malcolm Brenner (USA)
12:00 CLINICAL EXPERIENCE WITH LOCALLY-PRODUCED CAR-T AND TIL
Michal Besser (Israel)
12:20 CAR-T THERAPY FOR B CELL MALIGNANCIES
Jennifer Brogdon (USA)
12:40 XCELLERATE - NEXTGEN MANUFACTURING PLATFORM FOR IMPROVED CAR T
CELLS
Lothar Germeroth (Germany)
13:00-14:30 Zaragoza III & IV
Lunch, Poster Viewing, Networking & Exhibition
14:30 – 16:00 Zaragoza I & II
SESSION 2
FIGHTING SOLID TUMORS WITH ENGINEERED LYMPHOCYTES
Chair: Marcela Maus (USA)
14:30 TARGETING OF MULTIPLE TUMORS AND VIRAL-INFECTED CELLS USING T-CELLS
ENGINEERED TO EXPRESS NCR-BASED CHIMERIC RECEPTORS
Cyrille Cohen (Israel)
14:50 ENGINEERING T CELLS FOR THE IMMUNOTHERAPY OF SOLID TUMORS
Stephen Gottschalk (USA)
15:10 CAR T CELLS IN GLIOBLASTOMA AND OTHER SOLID TUMORS
Marcela Maus (USA)
15:30 ABSTRACT ORAL PRESENTATION
REDIRECTING SWITCHABLE UNICAR T CELLS FOR ELIMINATION OF
RADIORESISTANT CANCER CELLS
A. Feldmann, C. Arndt, R. Bergmann, N. Berndt, J. Jureczek, S. Albert, D. Lindner,
S. Koristka, J. Steinbach, G. Ehninger, M. Krause, I. Kurth, A. Dubrovska, M. Bachmann
(Germany)
15:45 ABSTRACT ORAL PRESENTATION
IMPROVING THE EXPANSION AND PERSISTENCE OF CAR T CELLS USING
ONCOLYTIC RHABDOVIRAL VACCINE VECTORS IN PAEDIATRIC SARCOMAS
F. Zemp, J. Rajwani, K. Potts, S. Van, D. Mahoney (Canada)
12INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
16:00-16:40 Zaragoza III & IV
Coffee Break, ePoster Presentations & Poster Viewing, Networking & Exhibition
EPOSTER SESSION 1
HEMATOLOGICAL MALIGNANCIES
Chair: Sonia Guedan (Spain)
16:10 LYMPHOCYTE-SPECIFIC DELIVERY OF PROTEIN THERAPEUTICS BY GENETICALLY
ENGINEERED EXOSOMES
D. Levy, M. Do, B. Lu (USA)
16:20 SUPER-RESOLUTION MICROSCOPY DSTORM REVEALS CD19DIM EXPRESSION ON A
SUBSET OF MYELOMA CELLS THAT CAN BE TARGETED WITH CD19-CAR T CELLS
T. Nerreter, S. Letschert, S. Doose, S. Danhof, H. Einsele, M. Sauer, M. Hudecek
(Germany)
16:30 ENGINEERING CD38LOW NATURAL KILLER CELLS TO TRANSIENTLY EXPRESS
CD16 (F158V) M-RNA ENHANCES THE CYTOTOXIC POTENTIAL OF DARATUMUMAB
AGAINST MULTIPLE MYELOMA WITH MINIMAL NK CELL FRATRICIDE
S. Sarkar, S. Chauhan, A. Natoni, J. Daly, R. Henderson, M. O'Dwyer (Ireland)
16:40 – 17:50 Zaragoza I & II
SESSION 3
NON VIRAL VECTORS AND TRANSPOSONS
Chair: Michael Hudecek (Germany)
16:40 ENGINEERING LYMPHOCYTES WITH RNAI NANOMEDICINES
Dan Peer (Israel)
17:00 NEW TARGETS AND TECHNOLOGIES FOR CAR-T
Michael Hudecek (Germany)
17:20 Abstract Oral presentation
VAPOR NANOBUBBLE PHOTOPORATION AS A NEW, SAFE AND EFFICIENT
TECHNIQUE FOR THE DELIVERY OF SMALL INTERFERING RNA TO CYTOTOXIC T
CELLS
J. Van Hoeck, L. Wayteck, R. Xiong, K. Braeckmans, S.C. De Smedt, K. Raemdonck
(Belgium)
17:35 CRISPR/CAS9 UNITES WITH SLEEPING BEAUTY TO GENERATE CAR T CELLS WITH
ENHANCED THERAPEUTIC INDEX FOR FIGHTING AGAINST IMMUNOSUPPRESSIVE
TUMOR MICROENVIRONMENT
R. Monjezi, C. Miskey, T. Stüber, E. Grueso, M. Schleef, M. Schmeer, H. Einsele, Z. Ivics,
M. Hudecek (Germany)
18:30 NETWORKING WELCOME RECEPTION
More info on p. 24.
#ICLE2018 13FRIDAY, 14 SEPTEMBER 2018
08:30 – 10:20 Zaragoza I & II
SESSION 4
GENOME EDITING AND ALLOGENEIC ACT
Chair: Ayal Hendel (Israel)
08:30 GENE EDITED ALLOGENEIC T CELL THERAPIES
Waseem Qasim (UK)
08:50 CRISPR GENE CORRECTION FOR HEMATOPOIETIC STEM CELLS
Ayal Hendel (Israel)
09:10 GENE EDITED UNIVERSAL OFF-THE-SHELF IMMUNOTHERAPIES: A FUTURE-
DEFINING SHIFT IN SIMPLICITY, AVAILABILITY, AND COST-EFFECTIVENESS
André Choulika (USA)
09:30 MEGATAL TARGET GENE DISRUPTION FOR THE ENHANCEMENT OF T CELL
THERAPIES
Michael Magee (USA)
09:50 ABSTRACT ORAL PRESENTATION
GENERATION OF "OFF-THE SHELF" αCD19-CAR T CELLS FOR THE TREATMENT OF
B CELL MALIGNANCIES
M. Tristán-Manzano, R. Martín-Guerra, N. Maldonado, S. Sánchez-Hernández,
M. Cortijo, C. Marañon, C. Herrera, M.D. Carmona, J.A. Marchal, K. Benabdellah,
F. Martín (Spain)
10:05 ABSTRACT ORAL PRESENTATION
GENOME EDITING USING ARCUS HOMING ENDONUCLEASES AND AN OPTIMIZED
MANUFACTURING PROCESS FOR PRODUCTION OF OFF-THE-SHELF ALLOGENEIC
CAR T THERAPIES
B. Mccreedy, A. Martin, D. MacLeod, C. Pham, A. Brown, J.A. Hux, J. Lape, C. Beard,
J. Smith, K. Nguyen, V. Senyukov, J. Anthony, K. Sivarajan, L. Som, M. Triggiano,
D. Jantz (USA)
10:20 – 11:00 Zaragoza III & IV
Coffee Break, ePoster Presentations & Poster Viewing, Networking & Exhibition
EPOSTER SESSION 2
SAFETY SWITCHES & CONTROLLED EXPRESSION/
HEMATOLOGICAL MALIGNANCIES
Chair: Tal Akriv (Israel)
10:30 HIGHLY EFFICIENT AND SELECTIVE CAR-GENE TRANSFER USING CD4- AND CD8-
TARGETED LENTIVIRAL VECTORS
A. Jamali, L. Grimm, C.J. Buchholz, J. Hatrmann (Germany, Iran)
10:40 POST-TRANSPLANT IMMUNOTHERAPY WITH WT1-SPECIFIC CTLS FOR HIGH-RISK
ACUTE MYELOGENOUS LEUKEMIA: A PROSPECTIVE CLINICAL PHASE I/II TRIAL
H.J. Kim, H.J. Sohn, J.A. Hong, H.J. Lee, D.H. Sohn, C.A. Shin, S.J. Hyun, C.H. Hong,
H. Choi, A.R. Shin, H.I. Cho, W.S. Min, T.G. Kim (Republic of Korea)
14INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
11:00-12:30 Zaragoza I & II
SESSION 5
NEW HORIZONS FOR LYMPHOCYTE AND HSC ENGINEERING
Chairs: Matthew Porteus (USA)
Beatriz Martin-Antonio (Spain)
11:00 HIGHLY EFFICIENT EDITING OF PRIMARY HUMAN BLOOD CELLS BY HOMOLOGOUS
RECOMBINATION
Matthew Porteus (USA)
11:20 ENGINEERING REGULATORY T-CELL THERAPEUTICS
Andrew Scharenberg (USA)
11:40 ENGINEERING T CELLS AND B CELLS EX VIVO AND IN VIVO
Adi Barzel (Israel)
12:00 ABSTRACT ORAL PRESENTATION
NK CELLS FROM DIFFERENT SOURCES AS A PROMISING ALTERNATIVE FOR CAR-
BASED IMMUNOTHERAPY AGAINST HEMATOLOGICAL CANCERS
L. Herrera, A. Boronat, P. Zuñiga, I. Martin, J. Anguita, B. Marzal, S. Santos,
M.A. Vesga, F. Borrego, M. Juan, C. Eguizabal (Spain)
12:15 ABSTRACT ORAL PRESENTATION
HARNESSING CD8 CO-RECEPTOR FUNCTION FOR IMMUNOTHERAPY WITH LOW-
AVIDITY TCR TRANSGENIC T CELLS
G. Bajwa, E. Hoyer, D. Brenner, M. Martinez-Paniagua, N. Nouraee, F. Sadeghi,
I. Gruber, M. Hebeisen, N. Rufer, M.F. Wu, W. Tao, N. Varadarajan, M. Brenner, C. Arber
(Switzerland)
12:30-14:00 Zaragoza III & IV
LUNCH, PIPELINE PRESENTATIONS, NETWORKING & EXHIBITION
PIPELINE PRESENTATIONS
12:40 GENEWERK, TOWARDS SAFER THERAPIES
Wei Wang (GeneWerk Germany)
12:55 LENTIVIRAL VECTORS: SAFETY AND MANUFACTURING RELATED ASPECTS
Juan Carlos Ramírez (VIVEbiotech. Spain)
#ICLE2018 1514:00 – 15:30 Zaragoza I & II
SESSION 6
ENGINEERING LYMPHOCYTES TO CLEAR INFECTIONS
Chair: Paula Cannon (USA)
14:00 ENGINEERING RESISTANCE AND PERSISTENCE- T CELLS FIGHT BACK AGAINST
HIV
Bruce Levine (USA)
14:20 ENGINEERING HSC AND LYMPHOCYTES TO SUPPRESS HIV
Paula Cannon (USA)
14:40 ENGINEERING ANTIVIRAL CAR T CELL IMMUNITY THROUGH HEMATOPOIETIC
STEM/PROGENITOR CELLS
Scott Kitchen (USA)
15:00 ABSTRACT ORAL PRESENTATION
EVALUATION OF A FULLY HUMAN CAR FOR THE TREATMENT OF HEPATITIS B
VIRUS INFECTION IN AN IMMUNOCOMPETENT MOUSE MODEL
M. Festag, K. Wisskirchen, J. Hasreiter, S. Schreiber, H. Abken, U. Protzer (Germany)
15:15 ABSTRACT ORAL PRESENTATION
ANTIBODY-SECRETING T CELLS ENGINEERED FOR TRIPARTATE IMMUNE
RESPONSE AGAINST THE HIV RESERVOIR
A. Powell, Y. Ren, M. Korom, H. Goldstein, D.F. Nixon, C. Bollard, R.M. Lynch,
R.B. Jones, C.R. Cruz (USA)
15:30-16:10 Zaragoza III & IV
Coffee Break, ePoster Presentations & Poster Viewing, Networking & Exhibition
EPOSTER SESSION 3
TARGET & RECEPTOR DISCOVERY/NON-VIRAL VECTORS
Chair: Natalia Gritsenko (Israel)
15:40 DIMERISATION IS ESSENTIAL FOR HIGH LEVEL CYTOKINE SECRETION BY T CELLS
BEARING A CD28-BASED 2ND GENERATION CAR: POTENTIAL RELEVANCE FOR
CONTROLLING CYTOKINE RELEASE SYNDROME
A. Kilgallon, M. Kalaitsidou, G. Kueberuwa, A. Schutt, D.E. Gilham, R.E. Hawkins, (UK)
15:50 SURFACE MOBILITY AND CLUSTER FORMATION OF VARIOUS MELANOMA
ASSOCIATED ANTIGENS MODULATES CHIMERIC ANTIGEN RECEPTOR (CAR)
MODIFIED T CELL ACTIVATION
A. Szoor, A. Holzinger, A. Pham, H. Abken, G. Vereb (Hungary)
16:00 GENERATION OF WILMS’ TUMOR 1 TCR-REDIRECTED CD4 AND GAMMA-DELTA T
CELLS BY RNA ELECTROPORATION AND CO-TRANSFER OF CD8 MRNA
D. Campillo, G. Roex, H.H. Van Acker, Z.N. Berneman, E. Lion, V.F.I. Van Tendeloo
(Belgium)
16INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
16:10 – 17:40 Zaragoza I & II
SESSION 7
OPTIMIZING RECEPTOR AND VECTOR DESIGN
Chairs: Gideon Gross (Israel)
Julio Delgado (Spain)
16:10 FROM A CANCER CAUSING VIRUS TO A SAFER TOOL FOR GENE THERAPY AND
IMMUNOTHERAPEUTICS
Axel Schambach (Germany)
16:30 RECEPTOR-TARGETED VIRAL VECTORS IN IMMUNOTHERAPY
Christian Buchholz (Germany)
16:50 CAR T CELL THERAPY: THE CD19 PARADIGM
Xiuyan Wang (USA)
17:10 ABSTRACT ORAL PRESENTATION
OVERCOMING FRATRICIDE TO DELIVER A CLINICAL GRADE CAR T CELL PRODUCT
S. Bornschein, B. Demoulin, E. Breman, A. Michaux, J. Houssa, F. Huberty, B. Violle,
C. Jacques-Hespel, C. Marchand, J. Marijsse, T. Nguyen, N. Ramelot, D. Daro,
V. Steenwinckel, S. Agaugue, D. Gilham (Belgium)
17:25 ABSTRACT ORAL PRESENTATION
CELL THERAPY WITH ENGINEERED HLA-A2 SPECIFIC CAR-CD8+TREGS TO AVOID
TRANSPLANT REJECTION
S. Bezie, N. Vimond, V. Daguin, F. Bell ier-Waast, F. Duteille, M. Levings, B. Charreau,
I. Anegon, C. Guillonneau (France)
#ICLE2018 17SATURDAY, 15 SEPTEMBER 2018
08:30 – 10:00 Zaragoza I & II
SESSION 8
SAFETY SWITCHES & CONTROLLED EXPRESSION
Chairs: Daniel Powell (USA)
Francisco Martin Molina (Spain)
08:30 STRATEGIES FOR QUANTITATIVE CONTROL OF REDIRECTED GENE-ENGINEERED T
CELL ACTIVITY
Daniel Powell (USA)
08:50 USING MRNA FOR IMPROVING T CELL PERFORMANCE IN ADOPTIVE CELL
THERAPY
Gideon Gross (Israel)
09:10 ISOLATION AND IDENTIFICATION OF OPTIMAL T CELLS AND RECEPTORS FOR
ADOPTIVE IMMUNOTHERAPY
Dirk Busch (Germany)
09:30 ABSTRACT ORAL PRESENTATION
ARMING HUMAN REGULATORY T CELLS FROM HEALTHY DONORS OR MULTIPLE
SCLEROSIS PATIENTS WITH SWITCHABLE CHIMERIC ANTIGEN RECEPTORS FOR
THE TREATMENT OF INFLAMMATORY DISEASES
A. Kegler, S. Koristka, R. Bergmann, C. Arndt, A. Feldmann, S. Albert, G. Ehninger,
M. Bornhäuser, M. Schmitz, K. Akgün, T. Ziemssen, M. Bachmann (Germany)
09:45 ABSTRACT ORAL PRESENTATION
DEVELOPMENT OF CLINICAL-GRADE DOXYCYCLINE-INDUCIBLE CAR T CELLS
N. Maldonado, M. Tristán-Manzano, S. Sánchez-Hernández, C. Marañón, C. Herrera,
M.D. Carmona, F. Martin, K. Benabdellah (Spain)
10:00 – 10:30 Zaragoza III & IV
Coffee Break, ePoster Presentations & Poster Viewing, Networking & Exhibition
EPOSTER SESSION 4
SAFETY SWITCHES AND CONTROLLED EXPRESSION
Chair: Yuval Raviv (Israel)
10:10 ELIMINATION OF CAR-ENGINEERED LYMPHOCYTES BY AUTOLOGOUS ANTI-CAR T
CELLS
S. Koristka, P. Ziller-Walter, A. Feldmann, C. Arndt, A. Kegler, S. Albert, G. Ehninger,
M. Bornhäuser, M. Bachmann (Germany)
10:20 DEVELOPMENT AND CHARACTERIZATION OF NOVEL ANTI-GD2 TARGET MODULES
FOR RETARGETING OF UNIVERSAL CAR T CELLS TOWARD GD2 EXPRESSING
TUMORS
N. Mitwasi, A. Feldmann, R. Bergmann, N. Berndt, C. Rössig, M. Bachmann (Germany)
18INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
10:30-12:00 Zaragoza I & II
SESSION 9
NEW TARGETS AND NEW RECEPTORS
Chairs: Dinorah Morvinski (Israel)
Rafael Duarte (Spain)
10:30 DESIGNER T CELLS FOR IMMUNOTHERAPY OF CANCER
Wolfgang Uckert (Germany)
10:50 P32, A NOVEL TARGET OF CAR T-CELL THERAPY FOR GLIOMAS
Dinorah Friedmann-Morvinski (Israel)
11:10 DAYS OF THUNDER: CHALLENGES WHEN SEEKING NEW CARS
Barbara Savoldo (USA)
11:30 ABSTRACT ORAL PRESENTATION
CHIMERIC ANTIGEN RECEPTORS WITH A MYD88 AND CD40 ENDODOMAIN ENDOW
T CELLS WITH SUPERIOR ANTITUMOR ACTIVITY
B. Prinzing, G. Krenciute, S. Gottschalk (USA)
11:45 ABSTRACT ORAL PRESENTATION
A SEMI-AUTOMATED METHOD FOR THE ISOLATION AND INITIAL
CHARACTERIZATION OF NEOANTIGEN-SPECIFIC T CELL RECEPTORS
A. Bracher, D. Sommermeyer (Germany)
12:00-13:30 Zaragoza III & IV
Lunch, ePoster Presentations & Poster Viewing, Networking & Exhibition
EPOSTER SESSION 5
SOLID TUMORS/OTHER
Chair: Daniel Nataf (Israel)
12:10 TUMOR-ASSOCIATED FIBROBLASTS: GENERIC TARGET OF CANCER
IMMUNOTHERAPY
F. Bojin, O. Gavriliuc, V. Paunescu (Romania)
12:20 ACTIVE MODULATION OF THE TUMOR MICROENVIRONMENT BY ENGINEERED T
CELLS
E. Ceccarello, T. Tabaglio, D.W.K. Boon, W.K.L. Teo, D.Z.M. Tan, J.J.Y. Aw, S.S.F. Koh,
A. Pavesi, E. Guccione, A. Bertoletti (Singapore)
12:30 TARGETING MULTIPLE TUMORS AND VIRAL INFECTED CELLS USING T-CELLS
ENGINEERED TO EXPRESS A NCR-BASED CHIMERIC ANTIGEN RECEPTOR
V. Eisenberg, S. Hoogi, S. Mayer, K. Shamalov, T. Barliya, A. Pogrador, C.J. Cohen
(Israel)
12:40 FINE-TUNING OF CD28 SIGNALING MOTIFS INCREASES ANTI-TUMOR ACTIVITY
AND PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS
S. Guedan, A. Posey, A. Wing, V. Casado-Medrano, C. Shaw, R.M. Young, C.H. June
(Spain, USA)
#ICLE2018 1912:50 CAR-T CELL IMMUNOTHERAPY IN SOLID TUMORS: COLORECTAL CANCER
E. Ponterio, C. Valvo, M. Cappellari, L. Pasquini, A. Boe, P. Romania, E. Petrucci,
C. Amoreo, M.R. Sciuto, R. Dattilo, E. Pilozzi, L. Ricci-Vitiani, M. Biffoni, R. De Maria,
T.L. Haas (Italy)
13:00 ADOPTIVE T-CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA
L. Rousso Noori (Israel)
13:10 IMPROVING CEA-TARGETED CAR-T CELL THERAPY FOR SOLID TUMOURS
W. Zheng, G. Kueberuwa, E. Cheadle, A. Armstrong, R.E. Hawkins (UK)
13:20 ROLE PLAY BY GALECTIN-1 IN REGULATORY T-CELL IMMUNOTHERAPY FOR
MODULATION OF IMMUNE RESPONSES IN THE TREATMENT OF AUTOIMMUNE
DISEASES
R. Fernadez-Perez, O. Aberquilla-Fernandez, R. Sanchez-Dominguez, J.A. Bueren,
M.I. Garin (Spain)
13:30 – 15:35 Zaragoza I & II
SESSION 10
CONCLUDING KEYNOTE LECTURES
Chair: Adi Barzel (Israel)
13:30 WHAT’S NEXT? FROM PERSONALIZED TO “OFF THE SHELF” CARS
Anat Globerson Levin (Israel)
13:50 KEYNOTE LECTURE
T CELL THERAPY FOR CANCER
Carl June (USA)
14:35 PANEL DISCUSSION
LYMPHOCYTE ENGINEERING – WHAT’S NEXT?
Moderator: Adi Barzel (Israel)
Panelists:
Carl June (USA)
Malcolm Brenner (USA)
Jennifer Brogdon (USA)
André Choulika (USA)
15:35 CONCLUSIONS AND CLOSING ADDRESS
20INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018 RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT SUPPORTERS & EXHIBITORS START-UP INDUSTRY HUB SUPPORTER OF THE SCIENTIFIC SESSIONS PROGRAMME PARTNERS MEDIA PARTNERS #ICLE2018 21
EXHIBITOR & SUPPORTER
COMPANY PROFILES
CELLGENIX GMBH
Am Flughafen 16
79108 Freiburg
Germany
Booth # 2
www.cellgenix.com
GENEWERK GMBH
Im Neuenheimer Feld 582
D-69120 Heidelberg
Germany
Booth # TT5
www.genewerk.com
GeneWerk GmbH offers an integral platform for the analysis of gene therapy vectors
and designer nucleases safety in preclinical and clinical studies. DNA- or RNA-fusion
sequences are detected via PCR- and target enrichment-based approaches combined
with customized bioinformatics of next-generation sequencing data, thereby enabling
the identification of gene therapy vectors integration sites and gene editing on-/off-target
analysis. GeneWerk GmbH applications for immunotherapy also comprise the use of PCR-
or target enrichment-based workflows coupled to high-throughput sequencing for T and B
cell immunerepertoire studies. Dedicated bioinformatics complement our services to make
the most of our customer’s data and provide customized solutions.
22INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 181 Massachusetts Ave 4A-011-01-A Cambridge, MA 02139 USA www.novartis.com/our-science/novartis-institutes-biomedical-research Our mission is to discover new ways to improve and extend people`s lives. Our vision is to be a trusted leader in changing the practice of medicine. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. VIVEBIOTECH Mikeletegi Pasealekua 81, San Sebastián 20009, Gipuzkoa Spain Booth # 6 www.vivebiotech.com VIVEbiotech is a company fully specialized in lentiviral vectors with two areas of expertise: 1. GMP CDMO: GMP Contract Development and Manufacturing Organization specialized in lentiviral vector bioprocess development (from very early stages) and GMP manufacturing. Working with companies based in Europe and USA being flexible in terms of technical adaptation and slots availability. 2. Innovation: VIVEbiotech´ strategy is focused on providing a response to the main hurdles that currently exist within the gene therapy field: a. The need for cost-effective processes. b. The enhancement of the safety profile of viral vectors: worldwide licensed non- integrative episomal stable lentiviral vector (LENTISOMA). #ICLE2018 23
ICLE WELCOME RECEPTION
All delegates are welcome to an exciting welcome and networking reception on 13th
September, hosted at Santiago Bernabéu Stadium.
Pick Up Point: Melia Avenida America hotel lobby at 18:30
Departure time: 18:45 – 19:00
Transport & Location: There will be an organized bus service to Santiago Bernabeu
Stadium, entrance: Gate 44
Welcome reception: Emirates VIP Room 19:30 - 21:00
Returning time: 21:00 - 21:30
Drop off Points: Plaza de Espana and Melia Avenida America Hotel
24INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018 GETTING TO MADRID DOWNTOWN Melia Avenida America has good connections with the city centre. BY BUS The bus stop Ios Molinos is just next to the hotel from where you can take bus #146 to get to Callao Square (Plaza del Callao). BY METRO The closest metro station is Suanzes, within a 15 min walk from the hotel. To get to the center take line 5 (the green line, going to Casa de Campo) and travel to Gran Via or Callao (Plaza del Callao). The cost for a single trip is EUR 2. BY TAXI If you prefer to take a taxi from Melia Avenida America, getting to the downtown costs about EUR 20-25. ATTRACTIONS & SIGHTSEEING The Plaza Callao is famed as much for its role as the heart of cinematic and theatrical Madrid as it is for its eternal bustle and art deco style. Architecture, cinema buffs, many restaurants and trade centers, you will find much to discover here. The square is located just off the world famous Gran Via - one of the city’s main arteries and most iconic avenue, today known as the Spanish Broadway. The symbol of Gran Via is located on Calle Alcalá: the Metropolis Building, designed by Jules and Raymond Fevrier. In this area you will find luxury shops, boutiques and others. The second section, up to Plaza Callao, has a more American style, with the Telefónica building, Palacio de la Prensa and Palacio de la Música. The last branch reaches Plaza de España, with modern landmark buildings such as Lope de Vega and Carrión Building, also known as the Capitol. This is the Broadway Madrileña. The Gran Vía reaches Plaza de España through the central fountain monument of Miguel de Cervantes, surrounded by the Casa Gallardo, Edificio de la Compañía Asturiana de Minas, Torre de Madrid (142 meters) and the Building España (117 meters). GETTING TO ADOLFO SUÁREZ MADRID BARAJAS INTERNATIONAL AIRPORT There is a free of charge shuttle service for the hotel guests, available upon request. To use the shuttle, please go to hotel Reception and book your ride. #ICLE2018 25
NOTES 26
INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018
THANK YOU
FOR YOUR
PARTICIPATION!
#ICLE2018 27SAVE THE DATE
ADVANCING IMMUNO-GENE THERAPY
ACROSS DISEASES
INTERNATIONAL
CONFERENCE ON
LYMPHOCYTE
ENGINEERING
2019
12-14 SEPTEMBER
LONDON, UK
28 LYMPHOCYTE.KENES.COMYou can also read
